Skip to content
Home/Research/LL-37

LL-37 Research & Studies

We track 20 published, PubMed-indexed studies for LL-37, spanning 2020 to 2026. The research below includes 20 reviews.

View LL-37 details, dosing & pricing →
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
20
Reviews

LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review.

Review
Soman D, P J, et al.|Arch Oral Biol|2026
PubMed (PMID: 41544412)DOI: 10.1016/j.archoralbio.2026.106516

LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity.

Review
Keshri AK, Rawat SS, et al.|Int J Antimicrob Agents|2025
PubMed (PMID: 39643165)DOI: 10.1016/j.ijantimicag.2024.107398

Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review.

Review
He Y, Zhou Y, et al.|Int Immunopharmacol|2025
PubMed (PMID: 39954662)DOI: 10.1016/j.intimp.2025.114277

Decoding LL-37: Structure and antimicrobial mechanisms against microbial threats.

Review
Neshani A, Zare H, et al.|Infect Genet Evol|2025
PubMed (PMID: 41270816)DOI: 10.1016/j.meegid.2025.105853

Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.

Review
Svensson D, Nilsson BO|Inflamm Res|2025
PubMed (PMID: 40063262)DOI: 10.1007/s00011-025-02005-8

Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.

Review
Yuan Y, Li J, et al.|ACS Biomater Sci Eng|2025
PubMed (PMID: 40423576)DOI: 10.1021/acsbiomaterials.4c02029

Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.

Review
Voronko OE, Khotina VA, et al.|Int J Mol Sci|2025
PubMed (PMID: 40869425)DOI: 10.3390/ijms26168103

Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D.

Review
Connell T, Seidler K, Neil J|Nutr Res|2025
PubMed (PMID: 40517664)DOI: 10.1016/j.nutres.2025.05.006

Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease.

Review
Miao S, Liu H, et al.|Pharmacol Res|2024
PubMed (PMID: 39615616)DOI: 10.1016/j.phrs.2024.107529

The LL-37 domain: A clue to cathelicidin immunomodulatory response?

Review
Leite ML, Duque HM, et al.|Peptides|2023
PubMed (PMID: 37068711)DOI: 10.1016/j.peptides.2023.171011

Antibiofilm properties of cathelicidin LL-37: an in-depth review.

Review
Memariani H, Memariani M|World J Microbiol Biotechnol|2023
PubMed (PMID: 36781570)DOI: 10.1007/s11274-023-03545-z

Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.

Review
Memariani M, Memariani H|World J Microbiol Biotechnol|2023
PubMed (PMID: 38057654)DOI: 10.1007/s11274-023-03852-5

Regulation of LL-37 in Bone and Periodontium Regeneration.

Review
Chinipardaz Z, Zhong JM, Yang S|Life (Basel)|2022
PubMed (PMID: 36294968)DOI: 10.3390/life12101533

Cathelicidin LL-37 in Health and Diseases of the Oral Cavity.

Review
Tokajuk J, Deptuła P, et al.|Biomedicines|2022
PubMed (PMID: 35625823)DOI: 10.3390/biomedicines10051086

Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis.

Review
Aloul KM, Nielsen JE, et al.|Front Immunol|2022
PubMed (PMID: 35634307)DOI: 10.3389/fimmu.2022.880961

Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent.

Review
Vera-Cruz A, Tanphaichitr N, Angel JB|Clin Invest Med|2021
PubMed (PMID: 34600462)DOI: 10.25011/cim.v44i3.36657

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

Review
Ridyard KE, Overhage J|Antibiotics (Basel)|2021
PubMed (PMID: 34072318)DOI: 10.3390/antibiotics10060650

Structural Plasticity of LL-37 Indicates Elaborate Functional Adaptation Mechanisms to Bacterial Target Structures.

Review
Zeth K, Sancho-Vaello E|Int J Mol Sci|2021
PubMed (PMID: 34068993)DOI: 10.3390/ijms22105200

Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus.

Review
Moreno-Angarita A, Aragón CC, Tobón GJ|J Transl Autoimmun|2020
PubMed (PMID: 32743514)DOI: 10.1016/j.jtauto.2019.100029

Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections.

Review
Pahar B, Madonna S, et al.|Vaccines (Basel)|2020
PubMed (PMID: 32927756)DOI: 10.3390/vaccines8030517
View LL-37 Details← All Research